NCT02916693View on ClinicalTrials.gov

Mirabegron For Erectile Dysfunction

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

January 1, 2020

Study Completion Date

January 1, 2020

Conditions
Erectile DysfunctionOveractive BladderUrinary Incontinence
Interventions
DRUG

Mirabegron

FDA-approved, beta 3 agonist for over active bladder

Trial Locations (1)

21287

Johns Hopkins Medical Institutions, Baltimore

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT02916693 - Mirabegron For Erectile Dysfunction | Biotech Hunter | Biotech Hunter